BMS 582949, PS-540446
Bristol-Myers Squibb Company
Cas : 623152-17-0 Formula: C22H26N6O2
BMS-582949 had been in phase II clinical trials at Bristol-Myers Squibb for the oral treatment of moderate to severe psoriasis and for the treatment of rheumatoid arthritis (RA) in combination with methotrexate and for the treatment of inflammation in atherosclerotic plaque. However, no recent development has been reported for this research.
The present invention generally relates to a method of treating resistant rheumatic disease, such as refractory rheumatoid arthritis, with a therapeutically effective amount of a dual action p38 inhibitor that is safe and well-tolerated. A dual action p38 kinase inhibitor is a compound that inhibits both activation of p38 kinase and p38 kinase activity in cells.
A large number of cytokines participate in the inflammatory response, including IL- 1 , IL-6, IL-8 and TNF-a. Overproduction of cytokines such as IL-1 and TNF-a are implicated in a wide variety of diseases, including inflammatory bowel disease, rheumatoid arthritis, psoriasis, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer’s disease, and congestive heart failure, among others. See e.g., Henry et al., Drugs Fut. , 24: 1345- 1354 ( 1999); Salituro et al., Curr. Med. Ckem., 6:807-823 (1999)]. Important mediators of proinflammatory cytokines such as TNFct and IL-1 β,. as well as cellular responses to such cytokines production, are the mitogen-activated protein (MAP) kinases, and in particular, p38 kinase. See e.g., Schieven, G.L., “The biology of p38 kinase: a central role in inflammation”, Current Topics in Medicinal Chemistry, 5 :921 – 928 (2005). Accordingly, modulation of p38 kinase may be useful in the treatment of inflammatory disease including rheumatic diseases such as rheumatoid arthritis (RA).
Compounds that reportedly inhibit p38 kinase and cytokines such as IL-1 and TNF-a for use in treating inflammatory diseases are disclosed in U.S. Patent Nos.
6,277,989 and 6, 130,235 to Scios, Inc; U.S. Patent. Nos. 6, 147,080 and 5,945,41 8 to Vertex Pharmaceuticals Inc; U.S. Patent Nos. 6,251 ,914, 5,977, 103 and 5,658,903 to Smith-Kline Beecham Corp.; U.S. Patent Nos. 5,932,576 and 6,087,496 to G.D. Searle & Co.; WO 00/56738 and WO 01 /27089 to Astra Zeneca; WO 01/34605 to Johnson & Johnson; WO 00/12497 (quinazoHne derivatives as p38 kinase inhibitors); WO 00/56738 (pyridine and pyrimidine derivatives for the same purpose); WO 00/12497 (discusses the relationship between p38 kinase inhibitors); and WO 00/12074 (piperazine and piperidine compounds useful as p38 inhibitors). Other compounds that inhibit p38 kinase are pyrrolotriazine aniline compounds, information on these compounds is disclosed in U.S. Patent Nos. 6,670,357; 6,867,300; 7,034, 151 ; 7, 160,883; 7,21 1,666; 7,253, 167; and U.S. Publication Nos. 2003/023283 1 (published Dec. 18, 2003); 2004/0229877 (published Nov. 1 8, 2004); 2005/0043306 (published Feb. 24, 2005; 2006/0003967 (published Jan. 5, 2006); 2006/0030708 (published Feb. 9, 2006); 2006/0041 124 (published Feb. 23, 2006); 2006/0229449 (published Oct. 12, 2006); 2006/0235020 (published Oct. 19, 2006); and 2007/0213300 (published Sept 13, 2007).
In particular, WO 2003/090912 (U.S. Patent Nos. 7, 160,883, 7,388,009, p38 inhibitor, BMS-582949 (Example 7,
including processes of making and uses thereof.
Compounds having the formula (Id), above, wherein R4 has the values listed in the following Table, were prepared following the same procedure described for Example 3, using the appropriate amine in place of ra-butylamine.
EXAMPLE IA St
A solution of Example 1 (0.86 g, 2.20 mmol, 1.0 eq.) in THF (4.0 mL) and 1 N aqueous NaOH (9.0 mL, 4.1 eq.) was stirred at 6O0C overnight. After cooling to RT, the reaction mixture was concentrated in vacuo but not to dryness. To the solution at O0C was added 1 N aqueous hydrochloric acid until it was acidic and the precipitate was collected and dried to afford crude Example IA acid (0.51 g, 64.0 % yield). HPLC Ret. t. = 2.400 min.; LC/MS (M+H) + = 366.06+. The filtrate was then extracted with EtOAc (3x) and the organic layers were combined, dried over sodium sulfate, and concentrated in vacuo to give Example IA acid (0.035 g, 4.4 % yield). Part b.
A solution of Part a. acid (0.026 g, 0.071 mmol, 1.0 eq.), EDC (0.021 g, 0.11 mmol, 1.5 eq.), HOBt (0.015 g, 0.11 mmol, 1.5 eq), ^-propylamine (0.015 mL, 0.15 mmol, 2.1 eq.) and DIPEA (0.040 mL, 0.23 mmol, 3.2 eq.) in DMF (0.20 mL) was shaken at RT overnight. Water (1 mL) was added and the precipitate collected by filtration, washed with water, and dried to give Example IA amide (0.021 g, 70% yield); HPLC Ret. t. = 2.883 min.; LC/MS (M+H)+ = 421.18 +.
EJiAMPLE 2 Direct Aminolysis Procedure
Ester Compound I or Hexyllithium/THF
1. Aminolysis with hexyllithium
To a dried 100 ml flask was added THF (10 ml) under nitrogen, which was then cooled to -100C. Hexyllithium (2.3 M in hexane, 6.5 ml, 15.0 mmol) was added slowly (exothermic, temperature was up to 5°C), followed by dropwise addition of propylamine (1.01 g, 1.4 ml, 17.1 mmol) at such a rate to maintain the temperature below 5°C. The resulting mixture was stirred at O0C for 20 minutes. A suspension of ester compound I (1.0 g, 2.5 mmol) in THF (12 ml) was added over a 10 minute period (exothermic, T<5°C). After being stirred at 00C for 20 minutes, the mixture was allowed to warm to room temperature and stirred for 5 hours. Ester compound I was <0.1 AP at this point by HPLC analysis. The mixture was cooled to -50C. Acetic acid (2 ml) was added slowly to maintain the temperature <10°C. The resulting thick slurry was stirred at room temperature for 20 minutes, and then solvents were exchanged with DMF (15 ml) on a rotavapor. To the resulting yellow slurry, water (15 ml) was added slowly to keep T<25°C. During the addition of water, the slurry became a clear solution, and a new slurry was formed. The slurry was stirred at room temperature for overnight. In the morning the slurry was filtered and the solid was washed with DMF/water (1:1, 5 ml), water (5 ml) and acetone (5 ml). The cake was dried under vacuum at 55°C for 24 hours to afford 0.90 g of amide product II (yield: 87.2%) as a white solid. HPLC: 99.70 AP.
2. Aminolysis with n-butyllithium
To a dried 100 ml of flask was added THF (10 ml) under nitrogen and then cooled to -100C. n-Butyllithium (2.5 M in hexane, 6.0 ml, 15.0 mmol) was added slowly, followed by dropwise addition of propylamine (0.98 g, 16.5 mmol) at such a rate to keep the temperature below 00C. The resulting mixture was stirred at O0C for 20 minutes. A suspension of ester compound I (1.0 g, 2.5 mmol) in THF (12 ml) was added over a 10 minute period (T<5°C). After being stirred at O0C for 30 minutes, the mixture was allowed to warm to room temperature and stirred for overnight (~22h, Note 1). Compound I was not detected at this point by HPLC analysis. The mixture was cooled to -7°C. Acetic acid (2 ml) was added dropwise to maintain the temperature <10°C. The resulting thick slurry was stirred at 50C for 2 hours and at room temperature for 20 minutes, followed by evaporation on a rotavapor to give a wet yellow solid. To this solid was added acetone (10 ml) and water (20 ml). The slurry was stirred at room temperature for one and half hours. Filtration gave a white solid. This solid was washed with 35% acetone in water (10 ml), water (5 ml) and acetone (5 ml). The cake was dried under vacuum at 55°C for the weekend to afford 0.94g of amide product II (yield: 91.0%) as a white solid. HPLC: 99.76 AP. Note 1: Compound I was -0.056 AP at 2.5 hours.
Discovery of 4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38a MAP kinase inhibitor for the treatment of inflammatory diseases
J Med Chem 2010, 53(18): 6629
The discovery and characterization of 7k (BMS-582949), a highly selective p38α MAP kinase inhibitor that is currently in phase II clinical trials for the treatment of rheumatoid arthritis, is described. A key to the discovery was the rational substitution of N-cyclopropyl for N-methoxy in 1a, a previously reported clinical candidate p38α inhibitor. Unlike alkyl and other cycloalkyls, the sp2 character of the cyclopropyl group can confer improved H-bonding characteristics to the directly substituted amide NH. Inhibitor 7k is slightly less active than 1a in the p38α enzymatic assay but displays a superior pharmacokinetic profile and, as such, was more effective in both the acute murine model of inflammation and pseudoestablished rat AA model. The binding mode of 7k with p38α was confirmed by X-ray crystallographic analysis.
Ester Compound I
Amide Product II
A solution of n-propylamine (6.5 eq) in THF (20 ml/g of ester compound I) was cooled to — 5°C and was slowly treated with 2.5 M solution of n-butyllithium (6.1 eq). The mixture was stirred for 10 minutes. At the end of the period, a slurry of ester compound I (1 eq) in THF (14 ml/g of ester compound I) was cannulated into the performed Li-NHPr solution. The reaction mixture was warmed to 25°C and stirred till all of ester compound I was consumed (~ 3 hours). After the reaction was judged to be completed by HPLC, the reaction mixture was cooled to ~0°C and was slowly treated with acetic acid (5 ml/g of ester compound I). The slurry was then warmed to -2O0C and was stirred for 1 hour. At the end of the period, the solvent was distilled under vacuum to the minimum volume and the concentrated slurry was diluted with a solution of acetone (10 ml/g of ester compound I) and water (20 ml/g of ester compound I). The slurry was stirred for 1 hour and was cooled to ~5°C. The slurry was filtered and the cake was washed with acetone (5 ml/g of ester compound I). The cake was dried to give the amide product II (typically in 85% yield and 99 AP).
A solution of n-propylamine (20 eq) in 2,2,2-trifmoroethanol (10 ml/g of ester compound I) was slowly treated with 2.5 M solution of n-butyllithium (1.5 eq). The mixture was stirred for 5 minutes. At the end of the period, the starting material, ester compound I, was added and the reaction mixture was warmed to 900C. The reaction mixture was held at 900C for 24 hours and was allowed to cool to ~20°C. The reaction mixture was then analyzed by HPLC. Typically, analysis indicated there was only 1.57 AP of starting material left.
A solution of n-propylamine (2 eq) in methylene chloride (10 ml/g of ester compound I) at 200C was slowly treated with 2.0 M solution of trimethylaluminum (4 eq) in hexanes. The mixture was stirred for 15 minutes. At the end of the period, the starting material, ester compound 1 (1 eq), was added and the reaction mixture was warmed to 600C. The reaction mixture was held at 600C for 24 hours and was allowed to cool to ~20°C. The reaction mixture was then slowly quenched with aqueous HCl solution and analyzed by HPLC. Typically, analysis indicated there was 96.8AP of amide compound II product with 0.03 AP of the dipropylamide impurity.
|WO2003090912A1 *||15 abr. 2003||6 nov. 2003||Squibb Bristol Myers Co||Pyrrolo-triazine aniline compounds useful as kinase inhibitors|
Liu C, Lin J, Everlof G, Gesenberg C, Zhang H, Marathe PH, Malley M, Galella MA, McKinnon M, Dodd JH, Barrish JC, Schieven GL, Leftheris K.
Bioorg Med Chem Lett. 2013 May 15;23(10):3028-33. doi: 10.1016/j.bmcl.2013.03.022. Epub 2013 Mar 15.
Freebern WJ, Bigwarfe TJ, Price KD, Haggerty HG.
J Immunotoxicol. 2013 Jan-Mar;10(1):106-17. doi: 10.3109/1547691X.2012.736427. Epub 2012 Nov 23.
Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases.
Liu C, Lin J, Wrobleski ST, Lin S, Hynes J, Wu H, Dyckman AJ, Li T, Wityak J, Gillooly KM, Pitt S, Shen DR, Zhang RF, McIntyre KW, Salter-Cid L, Shuster DJ, Zhang H, Marathe PH, Doweyko AM, Sack JS, Kiefer SE, Kish KF, Newitt JA, McKinnon M, Dodd JH, Barrish JC, Schieven GL, Leftheris K.
J Med Chem. 2010 Sep 23;53(18):6629-39. doi: 10.1021/jm100540x.
Expert Opin Ther Pat. 2009 Aug;19(8):1165-8. doi: 10.1517/13543770902816160.
|WO2000012074A2||Aug 27, 1999||Mar 9, 2000||Sarvajit Chakravarty||Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase|
|WO2000012497A2||Aug 27, 1999||Mar 9, 2000||Sarvajit Chakravarty||Quinazoline derivatives as medicaments|
|WO2000056738A1||Mar 17, 2000||Sep 28, 2000||Astrazeneca Ab||Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease|
|WO2001027089A1||Oct 10, 2000||Apr 19, 2001||Astrazeneca Ab||Pyrimidine derivatives|
|WO2001034605A1||Oct 27, 2000||May 17, 2001||Ortho Mcneil Pharm Inc||SUBSTITUTED 2-ARYL-3-(HETEROARYL)-IMIDAZO[1,2-a]PYRIMIDINES, AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS|
|WO2003090912A1||Apr 15, 2003||Nov 6, 2003||Squibb Bristol Myers Co||Pyrrolo-triazine aniline compounds useful as kinase inhibitors|
|US4200750||Dec 8, 1977||Apr 29, 1980||Westwood Pharmaceuticals Inc.||4-Substituted imidazo [1,2-a]quinoxalines|
|US5658903||Jun 3, 1996||Aug 19, 1997||Smithkline Beecham Corporation||Cytokine inhibitors|
|US5932576||May 22, 1998||Aug 3, 1999||G. D. Searle & Company||3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors|
|US5945418||Mar 20, 1997||Aug 31, 1999||Vertex Pharmaceuticals Incorporated||Administering to the mammal to inhibit a mammalian protein kinase p38 which causes cell proliferation, cell death and response to extracellular stimuli|
|US5977103||Jan 10, 1997||Nov 2, 1999||Smithkline Beecham Corporation||Substituted imidazole compounds|
|US6087496||Apr 1, 1999||Jul 11, 2000||G. D. Searle & Co.||Enzyme inhibitors|
|US6130235||Aug 3, 1998||Oct 10, 2000||Scios Inc.||Piperidine moieties coupled to indole, benzimidazole or benzotriazole.|
|US6147080||Jun 10, 1997||Nov 14, 2000||Vertex Pharmaceuticals Incorporated||Inhibitors of p38|
|US6251914||Jul 1, 1998||Jun 26, 2001||Smithkline Beecham Corporation||Treating cytokine mediated diseases|
|US6277989||Mar 14, 2000||Aug 21, 2001||Scios, Inc.||Quinazoline derivatives as medicaments|
|US6670357||Nov 7, 2001||Dec 30, 2003||Bristol-Myers Squibb Company||Antiinflammatory agents|
|US6867300||Nov 6, 2002||Mar 15, 2005||Bristol-Myers Squibb Company||Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors|
|US7034151||Feb 5, 2004||Apr 25, 2006||Bristol-Myers Squibb Company||1,4-dihydro-4-oxo-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylates; novel approach to the formation of the bicyclic heterocyclic ring system|
|US7041501||Oct 31, 2002||May 9, 2006||Bristol-Myers Squibb Company||Methods of screening for toxicity of test compounds|
|US7160883||Apr 22, 2003||Jan 9, 2007||Bristol-Myers-Squibb Company||Pyrrolo-triazine aniline compounds useful as kinase inhibitors|
|US7211666||Dec 22, 2004||May 1, 2007||Bristol-Myers Squibb Company||N-Cyclopropyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; aminating with chloramine to produce a pyrrole with a Nitrogen nitrogen bond; reacting with formamide, cyclizing to form the pyrrolotriazine core; kinase inhibitors|
|US7253167||Jun 29, 2005||Aug 7, 2007||Bristol-Myers Squibb Company||Tricyclic-heteroaryl compounds useful as kinase inhibitors|
|US7388009||Oct 3, 2003||Jun 17, 2008||Bristol-Myers Squibb Company||Heterocyclic drugs as enzyme inhibitors for Kinase enzymes or prodrugs|
|US7462616||Oct 24, 2006||Dec 9, 2008||Bristol-Myers Squibb Company||Pyrrolo-triazine aniline compounds useful as kinase inhibitors|
|US7759343||Oct 28, 2008||Jul 20, 2010||Bristol-Myers Squibb Company||Pyrrolo-triazine aniline compounds useful as kinase inhibitors|
|US61379001||Title not available|
|US20030232831||Apr 22, 2003||Dec 18, 2003||Alaric Dyckman||Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors|
|US20040229877||Oct 29, 2003||Nov 18, 2004||Katerina Leftheris||Administering pyrrolotriazine carboxamide and benzamide compounds for therapy of p38 kinase-associated conditions|
|US20050043306||Oct 3, 2003||Feb 24, 2005||Katerina Leftheris||Heterocyclic drugs as enzyme inhibitors for Kinase enzymes or prodrugs|
|US20060003967||Jun 28, 2005||Jan 5, 2006||Zhongping Shi||Method for preparing pyrrolotriazine compounds|
|US20060030708||Aug 5, 2005||Feb 9, 2006||Lobben Paul C||Methods for the preparation of pyrrolotriazine compounds|
|US20060041124||Oct 14, 2005||Feb 23, 2006||Bang-Chi Chen||Process for preparing pyrrolotriazine kinase inhibitors|
|US20060229449||Apr 3, 2006||Oct 12, 2006||Apurba Bhattacharya||Reacting with chloramine in presence of aqueous base, phase transfer catalyst; anti-cancer agents, kinase inhibitors|
|US20060235020||Apr 4, 2006||Oct 19, 2006||Soojin Kim||Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein|
|US20070213300||Mar 6, 2007||Sep 13, 2007||Bristol-Myers Squibb Company||Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors|